Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02175745 · OUTCOME

Number of Suspicious Lesions Identified by 18F FDOPA PET

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas · Source last updated 2017-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
suspicious lesion(s)
Interval / dispersion
Not reported
Time frame
Up to 30 minutes after injection of F18 FDOPA

What was measured

The number of suspicious lesions will be identified by uptake of F18 FDOPA radiopharmaceutical using a positron emission tomography (PET) scan. Uptake of F-18 FDOPA is a measure of amino acid uptake and metabolism in tumors. Suspicious lesions will be visually identified by a board certified nuclear medicine physician.

Groups in this outcome

Diagnostic (FDOPA-PET/CT or PET/MRI)

Patients receive 18F-FDOPA intravenously (IV) and then undergo PET/CT or PET/MRI 10-30 minutes later. After completion of study, patients are followed up at 24 hours and at 1 week.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Diagnostic (FDOPA-PET/CT or PET/MRI)1

Reported measurements

Source class 1
Values in suspicious lesion(s) · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Diagnostic (FDOPA-PET/CT or PET/MRI)1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
The number of suspicious lesions will be identified by uptake of F18 FDOPA radiopharmaceutical using a positron emission tomography (PET) scan. Uptake of F-18 FDOPA is a measure of amino acid uptake and metabolism in tumors. Suspicious lesions will be visually identified by a board certified nuclear medicine physician.
groups
  1. description
    Patients receive 18F-FDOPA intravenously (IV) and then undergo PET/CT or PET/MRI 10-30 minutes later. After completion of study, patients are followed up at 24 hours and at 1 week.
    id
    OG000
    title
    Diagnostic (FDOPA-PET/CT or PET/MRI)
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 30 minutes after injection of F18 FDOPA
title
Number of Suspicious Lesions Identified by 18F FDOPA PET
type
PRIMARY
unit Of Measure
suspicious lesion(s)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice